Trial Profile

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2025 According to a ViiV Healthcare media release, data from this study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025),
12 Mar 2025 Results presented in the ViiV Healthcare Media Release
06 Mar 2024 Results assessing the accuracy of indirect PrEP adherence measures with drug concentrations in dried blood spots (DBS) among YMSM and TGW enrolled in the ImPrEP study, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com